Pre-exposure prophylaxis (PrEP) is a daily pill taken by HIV-negative people to prevent HIV infection. It can also be taken on demand before and after sex. The medicine stops the virus from getting ...

NICE has recommended a standardised approach for rehabilitation, to address the variation of care experienced by millions of people with chronic neurological conditions.

Suggested remit: To appraise the clinical and cost effectiveness of lecanemab within its marketing authorisation for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease.

Health technologies are reshaping healthcare, opening up new ways to care for patients, diagnose conditions earlier, and help people stay healthier for longer. From wearables to A ...

Suggested remit: To appraise the clinical and cost effectiveness of eflornithine within its marketing authorisation for treating high-risk neuroblastoma with complete or partial response after ...

This guideline has been updated and replaced by NICE guideline NG123.

May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COPD see our guideline on diagnosing ...

Our independent committee is calling on healthcare services to offer structured advice and follow-up support for people after they complete weight management treatment. Research shows that many people ...

This guideline covers the period before, during and after a young person moves from children's to adults' services. It aims to help young people and their carers have a better experience of transition ...

There is a simple discount patient access scheme for marstacimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

We have withdrawn this guideline and incorporated the relevant recommendations from it into NICE's antimicrobial prescribing guidelines on sinusitis, sore throa ...

Evidence-based recommendations on betula verrucosa (Itulazax 12 SQ Bet) for treating moderate to severe allergic rhinitis or conjunctivitis caused by pollen from trees in the birch allergy group in ...